



# Biotech Daily

Tuesday March 5, 2019

*Daily news on ASX-listed biotechnology companies*

- \* **ASX DOWN, BIOTECH UP: KAZIA UP 9%; LBT DOWN 6%**
- \* **MEDLAB, PHARMASCIENCE NANABIS DEAL**
- \* **TOTAL BRAIN, BLACKTHORN PARTNER FOR NEURO-BEHAVIOR**
- \* **PINACLE'S HYPERION TAKES 5% OF COCHLEAR, AGAIN**
- \* **JERSEY'S D&A INCOME TAKES 7% OF PHARMAXIS**
- \* **LEYDIN, POLONSKY REPLACE ALCHEMIA'S GENNARI, BOOK**
- \* **G MEDICAL APPOINTS PROF ZEEV ROTSTEIN DIRECTOR**

## MARKET REPORT

The Australian stock market fell 0.29 percent on Tuesday March 5, 2019, with the ASX200 down 18.1 points to 6,199.3 points.

Sixteen of the Biotech Daily Top 40 stocks were up, 12 fell, nine traded unchanged and three were untraded. All three Big Caps were down.

Kazia was the best, up 4.5 cents or 8.8 percent to 55.5 cents with 133,167 shares traded.

Cyclopharm climbed 8.4 percent; Immutep was up 6.25 percent; Paradigm and Patrys improved five percent or more; Avita, Pro Medicus and Proteomics were up more than three percent; Clinuvel and Prana rose more than two percent; Dimerix, Ellex, Genetic Signatures and Medical Developments were up more than one percent; with Mesoblast and Neuren up by less than one percent.

LBT led the falls, down 0.4 cents or 5.7 percent to 6.6 cents with 143,238 shares traded.

Antisense lost five percent; Impedimed, Prescient and Universal Biosensors fell four percent or more; Benitec and Nanosonics were down more than three percent; Starpharma shed 2.8 percent; Actinogen, Compumedics, Resmed and Volpara were down more than one percent; with Cochlear, CSL and Cynata down by less than one percent.

### MEDLAB CLINICAL

Medlab says it has an agreement with the Quebec, Montreal-based Pharmascience to develop and distribute its cannabis-based buccal spray Nanabis.

Medlab said the heads of agreement would allow the companies to negotiate research, regulatory and commercial milestones, including where Nanabis would be distributed.

The company said that Nanabis was currently in a clinical trial for cancer pain.

Medlab was up 2.5 cents or seven percent to 38 cents.

### TOTAL BRAIN

Total Brain says it has a partnership with Blackthorn Therapeutics to provide access to its Ispot-d depression study to target patients with neurobehavioral disorders.

Total Brain said the San Francisco-based Blackthorn would access a subset of its 1,800-patient five country Ispot-d depression study, to use in its computational psychiatry platform.

The company said the platform used data to solve patient selection problems in central nervous system drug discovery and development.

Total Brain fell 0.1 cents or 3.85 percent to 2.5 cents.

### COCHLEAR

Hyperion Asset Management says it has become a substantial shareholder in Cochlear with 2,931,961 shares or 5.08 percent of the company.

The Brisbane-based Hyperion said it bought and sold shares between February 13, 2018 and February 28, 2019 with the single largest acquisition of 57,311 shares for \$8,001,664 or \$139.62 a share; and the single largest sale 57,701 shares for \$11,489,381 or \$199.12 a share.

Hyperion first became a substantial shareholder in the company in 2011 and has traded above and below the five percent substantial level several times since then (BD: Mar 16, 2011).

Last year, a Pinnacle Investment Management executive told Biotech Daily that it owned 49 percent of Hyperion, which became a substantial in Cochlear on March 13 and fell below five percent on March 23, 2018 (BD: Mar 13, Mar 23, 2018).

Cochlear fell 35 cents or 0.2 percent to \$173.50 with 308,295 shares traded.

### PHARMAXIS

D&A Income says it has become a substantial shareholder in Pharmaxis with 27,160,830 shares or 6.89 percent of the company.

The Jersey, Channel Islands-based D&A Income said it acquired the shares between June 7, 2011 and February 28, 2019, with a single largest acquisition on February 28, of 19,123,830 shares for \$5,021,153 or 26.255 cents a share.

Yesterday, Pharmaxis said Montoya Investments ceased its shareholding in the company, selling 19,123,830 shares for 26.25 cents a share (BD: Mar 4, 2019).

In its substantial shareholder notice, D&A Income failed to name the signatory as required under the Corporations Act 2001, but said that registered holders included Pershing Nominees and W B Nominees and gave its address as HSBC House, St Helier Jersey.

Pharmaxis was unchanged at 26.5 cents.

## ALCHEMIA

Alchemia says chief financial officer Melanie Leydin and Lynden Polonsky have replaced chairman Simon Gennari and director Darren Book, effective from March 4, 2019.

Alchemia said Ms Leydin was currently its chief financial officer and company secretary and was a chartered accountant, and Mr Polonsky worked for investment banks and had founded a corporate advisory firm.

The company said that director Cameron Petricevic would be appointed chairman and Michael Sapountzis would be appointed joint company secretary, from today.

Alchemia was unchanged at 0.9 cents with 1.1 million shares traded.

## G MEDICAL INNOVATIONS

G Medical says it has appointed Prof Zeev Rotstein as a director.

G Medical said Prof Rotstein was currently the Hadassah Medical Organization director-general and a professor at the Hebrew University of Jerusalem.

The company said Prof Rotstein was a consultant in the construction of medical facilities and trained in medicine at Tel Aviv University.

G Medical fell half a cent or 1.7 percent to 29 cents.